Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash from Operations (2016 - 2025)

Angiodynamics (ANGO) has disclosed Cash from Operations for 16 consecutive years, with 4661000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 88.48% year-over-year to 4661000.0, compared with a TTM value of 5601000.0 through Nov 2025, up 75.97%, and an annual FY2025 reading of 10128000.0, up 64.03% over the prior year.
  • Cash from Operations was 4661000.0 for Q4 2025 at Angiodynamics, up from 15914000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 18811000.0 in Q2 2025 and bottomed at 25899000.0 in Q3 2023.
  • Average Cash from Operations over 5 years is 1929250.0, with a median of 2207000.0 recorded in 2021.
  • The sharpest move saw Cash from Operations soared 286.35% in 2022, then plummeted 1014.31% in 2024.
  • Year by year, Cash from Operations stood at 1941000.0 in 2021, then skyrocketed by 286.35% to 7499000.0 in 2022, then decreased by 29.78% to 5266000.0 in 2023, then plummeted by 53.04% to 2473000.0 in 2024, then skyrocketed by 88.48% to 4661000.0 in 2025.
  • Business Quant data shows Cash from Operations for ANGO at 4661000.0 in Q4 2025, 15914000.0 in Q3 2025, and 18811000.0 in Q2 2025.